Clinical trial Recruiting at 2 sites Observational Ages 19 and up

I-SCRIBBLE: Tracking blood biomarkers after spinal cord injury

Official title: The International Spinal Cord Injury Blood Biomarker Longitudinal Evaluation (I-SCRIBBLE) Study

Run by AO Foundation, AO Spine · NCT06839300 · Data updated 2026-11-12

This project will test whether blood levels of NF-L and GFAP taken soon after a traumatic spinal cord injury can help predict whether someone will have motor-complete or motor-incomplete impairment at six months.

Quick facts

Study typeObservational
Ages19 Years and up
SexAll
Enrollment260 (estimated)
SponsorAO Foundation, AO Spine
Academic / other
Locations8 sites (Milwaukee, Wisconsin and 7 other locations)
StatusRecruiting
StartedFebruary 9, 2026
Main results expectedDecember 1, 2029
Study endsDecember 1, 2029
Registry record updatedOctober 1, 2026
Trial IDNCT06839300 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (aged 19 or older) with acute blunt traumatic spinal cord injury between C0 and L1 who can provide informed consent and have an initial blood draw within 24 hours of injury are ideal candidates.

Probably not a fit

People with penetrating spinal injuries, prior spinal cord injury, injuries outside C0–L1, or who cannot provide a blood sample within 24 hours are not eligible and would not benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with acute blunt (non-penetrating) spinal cord injury will be enrolled at participating hospitals and have blood drawn within 24 hours of injury, daily through Day 7, and again at 6 and 12 months. Samples (serum, plasma, and RNA/DNA aliquots) are processed locally then sent to a central lab in Vancouver for storage and analysis. NF-L and GFAP concentrations will be measured on the Quanterix Simoa platform and compared with clinical neurologic exams (including ISNCSCI) to see how well early biomarker levels stratify injury severity and predict 6-month motor outcome. A control group of adults with traumatic spinal column injury but no spinal cord injury will be enrolled for comparison.

Why it matters

Potential benefit: If successful, this could provide an early blood test to help predict long-term motor outcome after traumatic spinal cord injury.

How similar studies have gone: Prior research using NF-L and GFAP measured with ultrasensitive assays has shown promising correlations with neurologic injury severity in traumatic brain and spinal cord injury, but large multicenter longitudinal validation remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 19 years
* Blunt (non-penetrating) traumatic SCI
* Baseline neurologic impairment deemed "complete" (AIS grade A) or "incomplete" (AIS grade B, C, or D) based on clinical history/examination and/or diagnostic imaging
* Bony spinal level involvement between C0 and L1, inclusive
* Ability to have initial blood sample drawn within 24 hours of injury
* Treated either surgically or non-surgically
* Ability to provide informed consent according to the IRB/EC defined and approved procedures

Inclusion criteria for non-spinal cord injury spinal trauma control participants:

* Age ≥ 19 years
* Traumatic spinal fracture and/or dislocation between C0 and L1 (inclusive) without SCI
* Treated either surgically or nonsurgically
* Ability to have initial blood sample drawn within 24 hours of injury
* Ability to provide informed consent according to the IRB/EC defined and approved procedures

Exclusion Criteria:

* Penetrating SCI (eg, gunshot, stab)
* Previous SCI
* Isolated spinal injury below L1
* Isolated radiculopathy without fracture
* Isolated cauda equina injury
* Patients with known diagnosis of multiple sclerosis
* Preexisting thromboembolic disease or coagulopathy (disorders related to blood clotting), such as hemophilia or von Willebrand disease
* Patients who in the investigator's opinion will not be compliant with the study procedures and patients who have any other conditions/injuries that in the investigator's opinion would render the study procedures dangerous

Where it's running

  • Medical College of Wisconsin
    Milwaukee, Wisconsin, United States
    Recruiting
  • Clinica Alemana de Santiago
    Santiago, Vitacura, Chile
    Recruiting
  • Prince of Wales Hospital
    Sydney, Randwick NSW, Australia
    Not yet recruiting
  • Cajuru University Hospital
    Curitiba, Paraná, Brazil
    Terminated
  • Charité Berlin
    Berlin, Germany
    Not yet recruiting
  • Sri Balaji Action Medical Institute
    New Delhi, India
    Not yet recruiting
Show 2 more locations
  • MIddlemore Hospital
    Auckland, Otahuhu, New Zealand
    Not yet recruiting
  • King's College Hospital
    London, United Kingdom
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.